Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene recently launched FilterTool, a web-based application designed for the rapid diagnosis and research of rare genetic diseases. This application integrates with CentoCloud®, a CE-marked bioinformatics pipeline, to help users efficiently analyze genetic variants from Next Generation Sequencing (NGS) data. FilterTool allows medical professionals to select the top 25 most relevant variants from tens of thousands, significantly reducing diagnostic time. Powered by CENTOGENE's extensive Biodatabank, which includes data from approximately 700,000 patients across over 120 countries, FilterTool aims to enhance clinical decision-making and accelerate genetic research. It is one of the first applications to receive a CE mark under the new In Vitro Diagnostic Regulation (IVDR), reflecting its compliance with European regulatory standards.
Centogene, the life science partner specializing in rare and neurodegenerative diseases, has unveiled its conference schedule for April 2023. The company will attend significant events including:
- Pharma 2023 in Barcelona, Spain from April 18-20.
- American Academy of Neurology (AAN) Annual Meeting in Boston, U.S. from April 22-27.
- Digital Medical Expertise & Applications (DMEA) 2023 in Berlin, Germany from April 25-27.
Centogene invites attendees to arrange one-on-one meetings to explore collaboration opportunities in Pharma, CRO, and diagnostic sectors.
Centogene aims to offer data-driven solutions, integrating multiomic technologies through its Biodatabank, which includes around 700,000 patients from over 120 countries, advancing precision medicine in rare diseases.
Centogene N.V. (Nasdaq: CNTG) has launched NEW CentoGenome®, an advanced Next Generation Sequencing (NGS)-based assay aimed at improving diagnostic accuracy for rare and neurodegenerative diseases. This new test offers comprehensive whole genome sequencing, capable of detecting nearly all disease-causing variants in a single assay. By implementing a PCR-free approach, the test reduces bias and increases sequencing quality, especially in complex genetic regions. The CentoGenome assay includes integrated support for lifelong diagnostic confirmation. Centogene's Biodatabank, housing data from approximately 700,000 patients across over 120 countries, reinforces the assay's effectiveness. These developments are anticipated to enhance the capabilities of healthcare professionals in diagnosing and identifying treatment options more swiftly.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
